StatStrip Glucose Meter Recall Hits Hospitals in FDA's Most Serious Warning

The StatStrip glucose meter recall has put hospitals across the United States on alert, after the Food and Drug Administration (FDA) identified Nova Biomedical's StatStrip Glucose Hospital Meter System Gen 2.0 as the subject of its most serious type of recall. The problem is not that the meters measure blood sugar incorrectly. It is that a correctly measured result can end up in the wrong patient's medical record, and treatment decisions made from that record could then be wrong too. The FDA updated its public communication on October 30, 2026, clarifying what hospitals should do while they wait for a software update, and Nova Biomedical has said a phased rollout of that update is planned for November 2026.

Key Points

• The FDA has identified the Nova Biomedical StatStrip Gen 2.0 recall as its most serious type, warning the device may cause serious injury or death if used without correction.
• Only the Gen 2.0 model is affected: StatStrip Glucose Hospital Meter System model 63685 and Glucose Hospital Meter System Multipack model 66739, on all firmware versions.
• Previous patient or quality-control information can remain on screen after a new barcode scan, so a result can be filed under the wrong patient if the mismatch is not spotted.
• The glucose measurement itself is not affected, according to Nova Biomedical and the FDA; the danger is misidentification, not a wrong reading.
• As of October 5, 2026, Nova Biomedical had reported one serious injury and no deaths linked to the issue, and hospitals with an alternative meter are advised to stop using the affected devices until they are updated.

What Happened

The FDA first issued its communication on October 20, 2026, and then updated it on October 30 to clarify the recommended actions for users. At the centre of the action is a screen-retention error. When staff scan a patient identification barcode or a quality-control barcode, information from the previous patient or the previous quality-control test can remain displayed on the meter. If the operator accepts that screen without noticing the discrepancy, the next glucose result is recorded under the wrong patient or the wrong quality-control identification.

That distinction matters. A nurse or doctor looking at the record later sees a plausible number, with no obvious sign that it belongs to someone else. Insulin dosing, hypoglycaemia treatment and other glucose-management decisions are all made from that number. The FDA's warning is blunt: the device "may cause serious injury or death if you continue to use it without correction." The agency's updated instructions tell facilities to flag or remove any glucose result identified as incorrectly assigned, so that other clinicians know it is an error and do not use it to guide treatment, and to notify the treating clinical team promptly under the facility's own procedures for correcting erroneous entries in the electronic medical record.

Nova Biomedical issued a customer advisory in July 2026 and revised it on October 5, 2026. The company has placed a voluntary shipment hold on all new StatStrip Gen 2.0 systems while corrective actions are developed and validated, and it says verification and validation work for a software update is under way, with a phased rollout intended to begin in November 2026. The update is also expected to include non-safety-related improvements.

Background and Context

Hospital glucose meters are used very differently from the meters people keep at home. A single hospital device may test dozens of patients in a shift, moving from bed to bed, with each result linked to a patient by a barcode scan. That workflow is efficient, but it also means that any failure in the link between a result and a patient can spread quickly through a ward's records. The StatStrip system is designed for that professional, multi-patient setting, which is why a patient-identification fault is treated so seriously even though the underlying chemistry of the test is unaffected.

The FDA's recall system distinguishes between a correction, where a device stays in use under updated instructions, and a removal, where it is taken out of use. In this case the agency's communication describes both strands: updated instructions to follow until a software update is available, and advice that facilities with an alternative meter should stop using the affected StatStrip meter until it is updated if the defect occurs. The FDA also says affected devices should be removed from where they are used or sold until a software update is available. Hospitals are therefore being asked to check their inventory now, not when the update arrives.

StatStrip Glucose Meter Recall: What Went Wrong

The fault, as described by the FDA and Nova Biomedical, is a display-retention problem. After a barcode scan, the meter can keep showing information from the previous scan. The operator is expected to check the screen before accepting it, but in a busy ward, with back-to-back tests, that check is exactly the step most likely to be rushed. If the stale information is accepted, the chain breaks: the result is genuine, the patient attached to it is not.

The affected products are narrowly defined, and that precision is important for hospitals doing their checks. The recall covers the StatStrip Glucose Hospital Meter System, model 63685, and the Glucose Hospital Meter System Multipack, model 66739, both under device identifier 00385480636858, on all versions of firmware. It does not apply to previously released StatStrip models, including Gen 1.86 and earlier generations such as 1.0, 1.75 and 1.87. A hospital that finds only older models in its stock is not affected by this action, but it should still confirm the model number rather than assume it from the brand name alone.

For patients, the practical message is reassuring in one respect and serious in another. There is no suggestion that the meters produce inaccurate glucose readings, and no suggestion that home glucose meters are involved. The risk arises only in the hospital setting, where one device serves many patients and results flow into electronic records that guide treatment. Anyone concerned about a hospital glucose result should ask the care team to confirm that the result in the record matches the test that was performed, a check hospitals are now being told to make anyway.

Reactions and Quotes

The FDA's language leaves little room for interpretation. The agency says it has "identified this recall as the most serious type" and warns that the device "may cause serious injury or death if you continue to use it without correction." Its updated communication also instructs facilities to "ensure that any glucose result identified as incorrectly assigned to a patient's medical record is immediately flagged or removed," so that other healthcare providers know it is an error and do not use it to guide glucose management decisions.

Why It Matters

Glucose management is one of the most common interventions in hospital care. Low blood sugar can cause confusion, seizures and loss of consciousness; high blood sugar, left untreated, can lead to serious complications, particularly after surgery or during serious illness. Treatment decisions are often made quickly, on the basis of the most recent number in the chart. If that number belongs to another patient, the treatment that follows may be unnecessary, insufficient, or actively harmful, and the patient who actually needs treatment may go without it.

What Happens Next

The immediate next step is the phased software update Nova Biomedical intends to roll out in November 2026. Until a hospital's meters have received that update, the FDA's interim advice stands: follow the updated instructions, stop using an affected meter if an alternative is available and the defect occurs, and correct any misassigned results already in the record. Hospitals should also check with Nova Biomedical or their authorised distributor for the current instructions covering their region, since the manufacturer's global announcement lists additional regional products beyond the US list.

Frequently Asked Questions

Is my home glucose meter affected by the StatStrip recall?

No. The recall covers only Nova Biomedical's StatStrip Glucose Hospital Meter System Gen 2.0, used by hospitals for multiple patients. Home glucose meters are not included.

Are the glucose readings themselves wrong?

No. Nova Biomedical and the FDA both say the analytical performance of the test is not affected. The problem is that a correct result can be assigned to the wrong patient's record.

Which models are affected?

StatStrip Glucose Hospital Meter System model 63685 and Glucose Hospital Meter System Multipack model 66739, on all firmware versions. Earlier models, including Gen 1.86, are not affected.

What should hospitals do right now?

Check model numbers, follow Nova Biomedical's updated instructions, flag or remove any misassigned results and notify the treating team, and stop using an affected meter if an alternative is available until the software update is installed.

Has anyone been harmed?

As of October 5, 2026, Nova Biomedical had reported one serious injury and no deaths associated with the issue, according to the FDA.

Related coverage: Blood pressure medication recall: 3,744 bottles pulled over failed dissolution tests and Atorvastatin recall: 13,296 bottles of cholesterol pills pulled nationwide.